USFDA declines to approve expanded use of this Antipsychotic drug

The company resubmitted its application in February with a focus on Alzheimer’s patients.

96
Medicine
Picture: Pixabay

Last Updated on August 7, 2022 by The Health Master

Acadia Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (USFDA) has declined to approve the expanded use of its antipsychotic drug for treating psychosis related to Alzheimer’s disease.

The drug is sold under the brand name Nuplazid.

According to a report by the news agency Reuters, the health regulator concluded there were limitations in the interpretability of Acadia’s antipsychotic drug study and an additional study would be required.

Meanwhile, the U.S. regulator’s decision comes roughly a month after its panel of outside advisors voted 9-3 that available data does not support the conclusion that the drug, pimavanserin, was effective for the treatment of hallucinations and delusions in Alzheimer’s disease.

“We are disappointed with this outcome. “The treatment of Alzheimer’s disease psychosis continues to be an area of high unmet need for which there is no approved therapy,” Acadia Chief Executive Officer Steve Davis said, as quoted by news agency Reuters.


Also read: Drug for Alzheimer’s disease rolled out


This was Acadia’s second attempt to secure approval for expanded use of the drug. In April 2021, the USFDA told Acadia its clinical trial data was not sufficient to support the approval of pimavanserin in patients with dementia-related psychosis.

The company resubmitted its application in February with a focus on Alzheimer’s patients.

The drug is already approved for a similar indication in patients with Parkinson’s disease and brought in sales of $484 million last year.

(With inputs from Reuters)

USFDA declines to approve this Urinary Tract Infection Drug

USFDA declines to approve this Anti-seizure drug

USFDA declines to authorise this viral skin disease treatment

USFDA declines pediatric EUA for vaccine Covaxin

USFDA declines to approve Gilead’s HIV drug on this concern

USFDA declines to approve GSK’s HIV inj.

FDA Haryana busted a fake medicine factory

USFDA issues Form 483 for 6 observations to Jubilant Pharmova

USFDA gives final approval to market this anti-inflammatory skin cream

FDA Maharashtra seizes diagnostic kits being sold without license

9th edition of Indian Pharmacopoeia released: Details

Govt is set to ban Codeine-based Cough Syrups and formulations

NPPA extends timeline for trade margin capping of these 5 Medical Devices

Govt releases new National Standards for Blood Centres and Blood Transfusion

Drug prices: What is One-molecule, One-price policy ?

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner